Biogen Agrees To Develop Knopp’s Experimental ALS Drug

Biogen has partnered with Knopp Neurosciences to push forward the development of dexpramipexole, a drug which has shown promise in preserving motor function and extending survival of ALS patients. The deal for control of the orphan drug included a stock purchase, a cash payment, and incentives valued at roughly $345 million.

Click here to read more.

Share this: